biostudies-literatureCruz LRBritish Embassy Havana206-212https://www.ebi.ac.uk/biostudies/studies/S-EPMC7755077biostudies-literatureUnknown4(1)The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors <i>in vitro</i>; however, no anti-CK2 clinical approach has been investigated in COVID-19. This trial aimed to explore the safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients. A monocentric, controlled, and therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with COVID-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). Adverse events were classified by the WHO Adverse ReaACS pharmacology & translational scienceTreatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.PMC7755077CIGB-300/2020Cruz LRATENEA-Co-300 GroupTorres LMuzio VValenzuela CChacon DPerea SEThompson DDiaz PAGuillen GReyes RBaladron IPerera GPerez JRosales MPerez GVRodriguez RRamon ACVazquez MMValido YPerera YGarcia ASantana RVazquez-Bloomquist DMRittoles AGonzalez AfalseTreatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.The instrumental role of CK2 in the SARS-CoV-2 infection has pointed out this protein kinase as promising therapeutic target in COVID-19. Anti-SARS-CoV-2 activity has been reported by CK2 inhibitors <i>in vitro</i>; however, no anti-CK2 clinical approach has been investigated in COVID-19. This trial aimed to explore the safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer patients. A monocentric, controlled, and therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with COVID-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care alone (10 patients). Adverse events were classified by the WHO Adverse Rea2021-01-01T00:00:00Z2021 Feb2026-05-08T15:13:58.071Z2021-02-25T08:54:52ZS-EPMC77550773361517310.1021/acsptsci.0c00175